期刊
CLINICS IN LIVER DISEASE
卷 22, 期 1, 页码 175-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cld.2017.08.012
关键词
NAFLD; NASH; Treatment; Pharmacotherapy
资金
- Genfit Pharmaceuticals [GFT505B-216-1]
Treatment of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is focused on patients with NASH because they are at highest risk for progressive liver disease. Current first-line treatment consists of lifestyle modifications. Patients should lose at least 7% to 10% of body weight via a combination of physical exercise and calorie restriction dieting. Surgical or endoscopic surgery for weight loss can be considered in obese patients, depending on degree of excess body weight and comorbidities. There is no currently approved pharmacotherapy for NASH. Vitamin E and pioglitazone have the most evidence of therapeutic efficacy but have limitations. The treatment modality chosen should be individualized.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据